NPS Intelligence (beta)

Disclosed NPS & retention by vertical

Verticals  /  Pharma, medtech & health distribution  /  10x Genomics, Inc.
—
Latest disclosed NPS
no score published
1
NPS entries
0 with a number
2025
Years covered
1 entries in all

In their words

“But the customers come back to us for all the reasons I just mentioned. And we see that reflecting in our customer surveys in double-blind NPS, which are off the charts, especially relative to our competitors. All of these metrics trend in our direction under our leadership, we expect for our leadership to continue.”
— Serge Saxonov, Co-Founder and CEO, 10x Genomics, Inc. · Earnings call, Q3 2025 · 6 Nov 2025 · NI-9737B1E

NPS disclosures (1)

Search the database →

6 Nov 2025
NPSProgram

But the customers come back to us for all the reasons I just mentioned. And we see that reflecting in our customer surveys in double-blind NPS, which are off the charts, especially relative to our competitors. All of these metrics trend in our direction under our leadership, we expect for our leadership to continue.

— Serge Saxonov, Co-Founder and CEO, 10x Genomics, Inc. · Earnings call, Q3 2025 · 6 Nov 2025 · NI-9737B1E
Earnings call, Q3 2025 ↗

Retention disclosures (0)

Open in the retention database →

No retention figures yet.

Lighthouse companies in Pharma, medtech & health distribution

The whole vertical →

About these figures

Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.

NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.